Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Jaguar Health Price Performance

Shares of NASDAQ JAGX opened at $0.25 on Thursday. The firm has a 50-day simple moving average of $0.76 and a 200-day simple moving average of $0.97. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. Jaguar Health has a 52 week low of $0.23 and a 52 week high of $21.60.

Institutional Investors Weigh In On Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Virtu Financial LLC acquired a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned 0.22% of Jaguar Health at the end of the most recent quarter. 12.04% of the stock is currently owned by institutional investors and hedge funds.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.